ADVERTISEMENT
M & A
Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.
A ruling from Ireland’s High Court has cleared the way for Endo and Mallinckrodt to consummate their merger in early August.
The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.
Private equity firm EQT is taking control of Alvo group B2B business Adalvo, after striking a deal to acquire a majority stake from Aztiq, the investment vehicle of founder Róbert Wessman.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
Sino Biopharm will pay almost $1bn to acquire what target LaNova’s CEO described as an “exploding” pipeline, which includes six clinical-stage candidates in the oncology area.
Thibaut Mongon is out as Kenvue CEO, a post he’s held since J&J spun it out in July 2023, after the firm’s results came under increased investor scrutiny over the past year. The board appointed as interim CEO Kirk Perry, a board member since December who most recently headed technology, data and pre
An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.
Alvotech has acquired long-time partner Ivers-Lee to expand its in-house capacity for assembly and packaging ahead of key planned biosimilar launches in 2025, strengthening operational control and supporting global growth.
The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.
The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.